RESEARCH TRIANGLE PARK, NC - Metabolon, Inc., the leader in metabolomics-driven biomarker identification used for disease diagnosis and drug safety and efficacy testing, announced today the launch of mSelect™, a service offering that empowers researchers in early drug discovery to select the most promising and lowest-risk drug candidates for continued development.
Based on advanced metabolomic analysis where drug-induced biochemical changes are detected in a single assay system, mSelect provides an unbiased and nontargeted assessment of a compound's on- and off-target effects. Results from mSelect studies allow researchers to advance compounds with higher potential for success in subsequent stages of development. By improving candidate selection, mSelect offers insight into how a drug can be positioned in the market or, if required, how it can be repositioned.
"mSelect enables researchers in the early stages of drug discovery to prioritize lead candidates so the most viable compounds can be advanced with confidence," said Dr. John Ryals, president and CEO of Metabolon. "Unlike the results obtained from the targeted approaches offered in current solutions, mSelect analyzes activity across virtually the entire spectrum of pathways in a single test. Our mSelect solution gives a clear, comprehensive assessment of compound activity that allows drug developers to make informed decisions about the direction of their research."
Metabolon researchers analyze compounds or pellets and lysates from cells already dosed with a compound. Biological interpretation of the effects is provided by the company's team of biochemists so that candidates can be effectively chosen for advancement.
Metabolon is an industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Metabolon's patented technology dramatically impacts drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In 2006, Metabolon was awarded a patent that broadly covers the metabolomic methods used to identify biomarkers seen in patients with amyotrophic lateral sclerosis (ALS). For additional information, please visit www.metabolon.com.
© the trelys funds